Stock listing
NASDAQ:PLRX Pliant Therapeutics, Inc. Stock
Home listing (NASDAQ) of Pliant Therapeutics, Inc.
Follow Pliant Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:PLRX
$0.595 USD -0.066 (-10.0%)
Close on Nov 20, 2026
- Day range
- $0.572 – $0.614 USDNov 20, 2026
- Volume
- 933,400 sharesNov 20, 2026
- Market cap
- $36.89M USDAt the close on Nov 20, 2026 · price × 61.99M shares outstanding
- 52-week range
- $0.572 – $1.670 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $386,066 USDMedian day 326,684 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PLRX · Home | $0.595 USD | -0.066 (-10.0%) | 933,400 | $0.600 | $0.614 | $0.572 | $0.661 | Close on Nov 20, 2026 |
| Frankfurt:9PT | €0.531 EUR | -0.052 (-9.0%) | — | €0.548 | €0.548 | €0.531 | €0.583 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PLRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.595 | -0.066 | -10.0% | $0.600 | $0.614 | $0.572 | 933,400 | |
| $0.661 | +0.001 | +0.1% | $0.655 | $0.674 | $0.638 | 939,630 | |
| $0.660 | -0.033 | -4.8% | $0.697 | $0.712 | $0.651 | 787,559 | |
| $0.693 | -0.004 | -0.5% | $0.696 | $0.710 | $0.660 | 999,035 | |
| $0.697 | -0.043 | -5.8% | $0.740 | $0.754 | $0.690 | 876,379 | |
| $0.740 | -0.038 | -4.8% | $0.775 | $0.775 | $0.733 | 525,308 | |
| $0.778 | -0.008 | -1.0% | $0.786 | $0.786 | $0.760 | 270,142 | |
| $0.786 | -0.014 | -1.7% | $0.820 | $0.820 | $0.770 | 360,585 | |
| $0.800 | -0.010 | -1.2% | $0.806 | $0.837 | $0.790 | 288,543 | |
| $0.810 | -0.006 | -0.7% | $0.809 | $0.824 | $0.801 | 151,613 | |
| $0.816 | -0.036 | -4.2% | $0.850 | $0.850 | $0.795 | 340,323 | |
| $0.852 | -0.009 | -1.0% | $0.860 | $0.882 | $0.842 | 205,287 | |
| $0.861 | +0.022 | +2.6% | $0.835 | $0.864 | $0.835 | 146,338 | |
| $0.839 | -0.020 | -2.3% | $0.850 | $0.855 | $0.839 | 385,679 | |
| $0.859 | -0.001 | -0.1% | $0.856 | $0.883 | $0.840 | 169,524 | |
| $0.860 | -0.030 | -3.3% | $0.875 | $0.903 | $0.851 | 205,951 | |
| $0.890 | +0.033 | +3.8% | $0.857 | $0.890 | $0.845 | 118,076 | |
| $0.857 | +0.007 | +0.9% | $0.842 | $0.882 | $0.830 | 346,675 | |
| $0.850 | -0.014 | -1.6% | $0.867 | $0.899 | $0.837 | 298,915 | |
| $0.864 | -0.002 | -0.2% | $0.870 | $0.879 | $0.831 | 446,817 | |
| $0.865 | -0.021 | -2.3% | $0.900 | $0.900 | $0.851 | 289,803 | |
| $0.886 | -0.027 | -2.9% | $0.927 | $0.928 | $0.880 | 340,621 | |
| $0.912 | +0.014 | +1.5% | $0.903 | $0.940 | $0.896 | 319,686 | |
| $0.899 | -0.001 | -0.1% | $0.913 | $0.928 | $0.875 | 292,201 | |
| $0.900 | -0.073 | -7.5% | $0.970 | $0.985 | $0.890 | 582,722 | |
| $0.972 | +0.089 | +10.0% | $0.900 | $0.972 | $0.900 | 481,347 | |
| $0.884 | -0.084 | -8.7% | $0.961 | $0.977 | $0.884 | 988,883 | |
| $0.968 | -0.018 | -1.8% | $0.983 | $0.998 | $0.961 | 284,640 | |
| $0.986 | -0.034 | -3.3% | $1.030 | $1.030 | $0.986 | 272,193 | |
| $1.020 | +0.020 | +2.0% | $0.990 | $1.030 | $0.986 | 288,527 | |
| $1.000 | +0.010 | +1.0% | $1.000 | $1.034 | $0.981 | 568,045 | |
| $0.990 | -0.040 | -3.9% | $1.030 | $1.030 | $0.970 | 756,501 | |
| $1.030 | 0.000 | 0.0% | $1.040 | $1.040 | $1.010 | 276,386 | |
| $1.030 | -0.005 | -0.5% | $1.040 | $1.054 | $1.020 | 295,615 | |
| $1.035 | -0.015 | -1.4% | $1.060 | $1.065 | $1.030 | 402,811 | |
| $1.050 | -0.030 | -2.8% | $1.100 | $1.100 | $1.050 | 379,553 | |
| $1.080 | 0.000 | 0.0% | $1.090 | $1.090 | $1.070 | 238,681 | |
| $1.080 | 0.000 | 0.0% | $1.090 | $1.120 | $1.080 | 214,498 | |
| $1.080 | 0.000 | 0.0% | $1.080 | $1.100 | $1.071 | 349,131 | |
| $1.080 | -0.060 | -5.3% | $1.140 | $1.140 | $1.080 | 450,185 | |
| $1.140 | +0.015 | +1.3% | $1.130 | $1.150 | $1.110 | 398,028 | |
| $1.125 | -0.015 | -1.3% | $1.140 | $1.140 | $1.100 | 254,281 | |
| $1.140 | +0.030 | +2.7% | $1.120 | $1.150 | $1.110 | 326,684 | |
| $1.110 | 0.000 | 0.0% | $1.120 | $1.130 | $1.110 | 149,288 | |
| $1.110 | -0.020 | -1.8% | $1.130 | $1.130 | $1.090 | 438,690 | |
| $1.130 | +0.060 | +5.6% | $1.090 | $1.140 | $1.090 | 308,086 | |
| $1.070 | -0.050 | -4.5% | $1.120 | $1.170 | $1.070 | 983,068 | |
| $1.120 | -0.030 | -2.6% | $1.150 | $1.155 | $1.110 | 502,028 | |
| $1.150 | -0.020 | -1.7% | $1.160 | $1.180 | $1.150 | 208,878 | |
| $1.170 | +0.040 | +3.5% | $1.140 | $1.180 | $1.140 | 173,460 | |
| $1.130 | -0.020 | -1.7% | $1.130 | $1.160 | $1.130 | 299,397 | |
| $1.150 | +0.015 | +1.3% | $1.120 | $1.170 | $1.120 | 450,171 | |
| $1.135 | -0.025 | -2.2% | $1.110 | $1.175 | $1.110 | 682,891 | |
| $1.160 | +0.030 | +2.7% | $1.120 | $1.185 | $1.110 | 559,895 | |
| $1.130 | -0.030 | -2.6% | $1.150 | $1.170 | $1.130 | 299,287 | |
| $1.160 | +0.050 | +4.5% | $1.110 | $1.170 | $1.110 | 740,063 | |
| $1.110 | +0.010 | +0.9% | $1.110 | $1.128 | $1.100 | 267,479 | |
| $1.100 | -0.010 | -0.9% | $1.100 | $1.120 | $1.093 | 400,005 | |
| $1.110 | -0.040 | -3.5% | $1.150 | $1.150 | $1.110 | 233,141 | |
| $1.150 | -0.010 | -0.9% | $1.160 | $1.160 | $1.140 | 112,828 | |
| $1.160 | -0.030 | -2.5% | $1.190 | $1.190 | $1.150 | 135,090 | |
| $1.190 | +0.050 | +4.4% | $1.140 | $1.200 | $1.130 | 321,952 | |
| $1.140 | -0.015 | -1.3% | $1.140 | $1.150 | $1.120 | 316,089 | |
| $1.155 | +0.035 | +3.1% | $1.120 | $1.170 | $1.120 | 504,685 | |
| $1.120 | -0.050 | -4.3% | $1.188 | $1.188 | $1.120 | 401,768 |
- Ticker
- NASDAQ:PLRX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 24 slides
Latest news
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Nov 12, 2026
Closed $0.697 (-5.8%) on Nov 13, 2026
Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
Nov 9, 2026
Closed $0.80 (-1.2%) on Nov 9, 2026
Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
Oct 29, 2026
Closed $0.859 (-0.1%) on Oct 30, 2026
Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)
Oct 20, 2026
Closed $0.912 (+1.5%) on Oct 20, 2026
Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026
Oct 19, 2026
Closed $0.912 (+1.5%) on Oct 20, 2026
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
Sep 30, 2026
Closed $1.05 (-2.8%) on Oct 1, 2026
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
Aug 18, 2026
Closed $1.15 (+4.5%) on Aug 18, 2026
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Aug 11, 2026
Closed $1.07 (+3.9%) on Aug 12, 2026
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
Jul 13, 2026
Closed $1.14 (+1.8%) on Jul 13, 2026
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 21, 2026
Closed $1.21 (-1.6%) on May 22, 2026
Pliant Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 119 in all · newest Nov 12, 2026 · oldest 2020
- Decks
- 9 decks · latest September 2026
Where Pliant Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PLRX · Home listing · This page | NASDAQ | United States | USD |
| LS Exchange:A2P4YV | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2P4YV | Lang & Schwarz | Germany | EUR |
| BOATS:PLRX | BOATS | United States | USD |
| gettex:9PT | gettex | Germany | EUR |
| Dusseldorf:9PT | Dusseldorf | Germany | EUR |
| Frankfurt:9PT | Frankfurt | Germany | EUR |
| Munich:9PT | Munich | Germany | EUR |
| Stuttgart:9PT | Stuttgart | Germany | EUR |
| Tradegate:9PT | Tradegate | Germany | EUR |
Valuation
Price/book 0.3× against a median of 2.4×: the lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$104.2M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.06
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Pliant Therapeutics, Inc. · NASDAQ:PLRX | US$36.89M | −US$104.2M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.06 |
| OSE Immunotherapeutics SA · EURONEXT:OSE | US$38.31M | US$52.28M | n/a | 18.2× | n/a | 1.3× | n/a | 1.3× | n/a |
| KoBioLabs, Inc. · KRX:348150 | US$38.23M | US$6.96M | n/a | 0.1× | n/a | 1.8× | −6.4% | 0.2× | n/a |
| Sprint Bioscience AB · OMXSTO:SPRINT | US$38.02M | US$28.89M | 5.1× | 2.1× | 3.7× | 4.3× | 54.4% | 0.0× | n/a |
| Theralase Technologies Inc. · TSXV:TLT | US$37.89M | US$34.22M | n/a | 61.1× | n/a | 7.9× | −472.5% | 0.0× | 0.75 |
| Connect Biopharma Holdings Limited · NASDAQ:CNTB | US$37.15M | US$18.16M | n/a | 4.9× | n/a | 3.1× | n/a | 0.0× | 0.93 |
| Coiled Therapeutics PLC · LSE:COIL | US$37.13M | US$30.46M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | n/a |
| TaiRx, Inc. · TPEX:6580 | US$37.07M | US$28.61M | n/a | 33.8× | n/a | 3.3× | −793.3% | 0.0× | n/a |
| Arovella Therapeutics Limited · ASX:ALA | US$36.01M | US$26.51M | n/a | n/a | n/a | 3.8× | n/a | 0.0× | n/a |
| Grace Therapeutics, Inc. · NASDAQ:GRCE | US$35.97M | US$14.66M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.77 |
| Cantargia AB · OMXSTO:CANTA | US$35.59M | US$13.85M | 2.2× | 0.5× | 0.9× | 1.4× | 52.8% | 0.0× | n/a |
| Median of the others | US$37.14M | US$27.56M | 3.6× | 4.9× | 2.3× | 2.4× | −6.4% | 0.0× | 0.77 |
Forecasts
3 hold · 1 sell · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 2.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.44 · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Craig Blanchette | Senior Vice President, Research |
| David Raben | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Hoyoung Huh | Chairman |
| Bernard Coulie | Director |
| Darren Cline | Board Member |
| Flavia Borellini | Director |
| Gayle Crowell | Board Member |
| John Curnutte | Board Member |
| Robert Iannone | Director |
| Steve Krognes | Member |
| Thomas McCourt | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −5.8% |
| Q2 2026 | Aug 11, 2026 · After close | +3.9% |
| Q1 2026 | May 11, 2026 · After close | −1.7% |
| Q4 2025 | Mar 3, 2026 | +1.6% |
| Q3 2025 | Nov 6, 2025 · After close | +4.6% |
| Q2 2025 | Aug 7, 2025 · After close | −1.2% |
| Q1 2025 | May 8, 2025 · After close | −3.4% |
| Q4 2024 | Feb 25, 2025 · Before open | +4.6% |
| Q3 2024 | Nov 7, 2024 · After close | −1.3% |
| Q2 2024 | Aug 7, 2024 · After close | −2.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 6, 2024 · After close | 0.0% |
| Q4 2023 | Feb 27, 2024 · After close | −3.4% |
| Q3 2023 | Nov 9, 2023 · After close | −2.6% |
| Q2 2023 | Aug 9, 2023 · After close | +3.3% |
| Q1 2023 | May 9, 2023 · After close | +2.3% |
| Q4 2022 | Mar 9, 2023 · After close | −2.1% |
| Q3 2022 | Nov 8, 2022 · After close | −5.0% |
| Q2 2022 | Aug 8, 2022 · After close | +11.2% |
| Q1 2022 | May 9, 2022 · After close | +4.7% |
| Q4 2021 | Feb 28, 2022 · After close | +11.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 24 slides | September 2026 |
| Technical Presentation (May 2025) | Technical | 13 slides | May 2025 |
| ERS Congress 2024 | Conference | 13 slides | September 2024 |
| ERS Congress 2024 | Conference | 10 slides | September 2024 |
| AASLD: The Liver Meeting 2023 | Conference | 18 slides | November 2023 |
| ERS International Congress 2023 | Conference | 18 slides | Sep 10, 2023 |
| Investor Presentation (January 2023) | Investor deck | 70 slides | Jan 9, 2023 |
| 2022 New Directions in Biology and Disease of Skeletal Muscle Conference | Conference | 25 slides | November 2022 |
| Investor Presentation (January 2022) | Investor deck | 29 slides | Jan 10, 2022 |
IPO
Priced at US$16.00 a share on Jun 2, 2020.
- Price
- US$16.00 a share
- Shares offered
- 9,000,000 shares of common stock
- Offering size
- US$144 million
- Underwriters' option
- Up to 1,350,000 more shares
- Underwriters
- Citigroup, Cowen, Piper Sandler, Needham & Company · In the order on the cover
- Shares delivered
- On or about Jun 5, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 10, 2019 |
| Filed publicly | May 11, 2020 |
| Amended twice | Newest Jun 2, 2020 |
| Shares registered with an exchange | May 29, 2020 |
| Declared effective by the SEC | Jun 2, 2020 |
| Final prospectus, with the price | Jun 3, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 3, 2020 |
| EFFECT · Notice that a registration is effective | Jun 2, 2020 |
| S-1/A · Registration statement, amended | Jun 2, 2020 |
| CERT · Exchange's certificate of listing | Jun 1, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | May 29, 2020 |
| CORRESP · Letter to the SEC | May 29, 2020 |
| CORRESP · Letter to the SEC | May 29, 2020 |
| CORRESP · Letter to the SEC | May 26, 2020 |
| S-1/A · Registration statement, amended | May 26, 2020 |
| UPLOAD · Letter from the SEC | May 20, 2020 |
All 25 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | May 13, 2020 |
| S-1 · Registration statement | May 11, 2020 |
| CORRESP · Letter to the SEC | May 8, 2020 |
| UPLOAD · Letter from the SEC | Apr 24, 2020 |
| DRS/A · Draft registration statement, amended | Apr 10, 2020 |
| DRSLTR · Letter to the SEC with a draft | Apr 9, 2020 |
| UPLOAD · Letter from the SEC | Mar 26, 2020 |
| DRS/A · Draft registration statement, amended | Mar 16, 2020 |
| DRSLTR · Letter to the SEC with a draft | Jul 17, 2019 |
| DRS/A · Draft registration statement, amended | Jul 17, 2019 |
| UPLOAD · Letter from the SEC | Jun 28, 2019 |
| DRSLTR · Letter to the SEC with a draft | Jun 20, 2019 |
| DRS/A · Draft registration statement, amended | Jun 20, 2019 |
| UPLOAD · Letter from the SEC | Jun 6, 2019 |
| DRS · Draft registration statement | May 10, 2019 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 3, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1.58M | 9.69M | 7.57M | 41.8M | 57.1M | 0 | |
| Cost of revenue | 1.70M | 2.13M | 1.84M | 3.68M | 3.20M | 666.0K | |||
| Gross profit | -1.70M | -2.13M | 1.58M | 9.69M | 7.57M | 41.8M | 57.1M | -666.0K | |
| Research and development | 109.2M | 169.3M | 127.8M | 96.9M | 77.5M | 66.2M | 47.4M | 24.4M | 14.5M |
| Selling, general and administrative | 47.2M | 59.1M | 57.9M | 39.9M | 27.6M | 17.3M | 10.9M | 6.50M | 3.82M |
| Operating income | -156.4M | -228.4M | -184.1M | -127.2M | -97.5M | -41.6M | -1.23M | -30.9M | -18.3M |
| Depreciation and amortization | 1.70M | 2.13M | 1.84M | 1.82M | 1.53M | 1.31M | 1.11M | 666.0K | 292.0K |
| EBITDA | -154.7M | -226.2M | -182.3M | -125.4M | -96.0M | -40.3M | -118.0K | -30.2M | -18.1M |
| Interest expense | 2.56M | 3.02M | 1.27M | 791.0K | 0 | 366.0K | 216.0K | 0 | 0 |
| Income before tax | -149.3M | -210.3M | -161.3M | -123.3M | -97.3M | 41.5M | 600.0K | -30.3M | -18.3M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 639.0K | 2.29M |
| Net income | -149.3M | -210.3M | -161.3M | -123.3M | -97.3M | -41.5M | -631.0K | -30.3M | -20.6M |
| Earnings per share, basic | -2.43 | -3.47 | -2.75 | -2.94 | -2.71 | -1.95 | -4.22 | -1.83 | -25.67 |
| Earnings per share, diluted | -2.43 | -3.47 | -2.75 | -2.94 | -2.71 | -1.95 | -4.22 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 45.4M | 71.2M | 63.2M | 33.7M | 51.7M | 50.9M | 85.8M | 60.9M | 4.25M |
| Short-term investments | 145.5M | 284.5M | 431.0M | 297.5M | 148.9M | 226.0M | 17.0M | 0 | |
| Receivables | 823.0K | 2.30M | 0 | 1.98M | 2.00M | 9.28M | 7.05M | 500.0K | 250.0K |
| Inventory | 1 | 1 | |||||||
| Current assets | 196.4M | 362.3M | 505.5M | 340.3M | 209.4M | 290.8M | 111.9M | 61.7M | 4.71M |
| Property, plant and equipment | 2.94M | 5.53M | 3.57M | 4.49M | 4.61M | 4.32M | 4.08M | 4.26M | 1.85M |
| Total assets | 225.2M | 396.9M | 512.2M | 350.6M | 221.2M | 295.5M | 119.1M | 66.5M | 6.55M |
| Accounts payable | 480.0K | 5.96M | 4.53M | 1.58M | 2.97M | 2.02M | 1.25M | 2.58M | 1.59M |
| Current liabilities | 16.4M | 33.2M | 28.5M | 23.9M | 16.8M | 11.6M | 8.17M | 5.08M | 3.19M |
| Long-term debt | 30.2M | 10.1M | 9.93M | ||||||
| Total debt | 0 | 30.2M | 10.1M | 9.93M | 0 | 283.0K | 444.0K | 525.0K | |
| Total liabilities | 44.0M | 92.9M | 38.6M | 37.3M | 22.2M | 12.5M | 9.08M | 67.4M | 3.19M |
| Shareholders' equity | 181.2M | 304.1M | 473.6M | 313.3M | 199.1M | 283.1M | -76.3M | -882.0K | 3.35M |
| Shares outstanding | 61.4M | 60.9M | 59.9M | 48.9M | 36.1M | 35.6M | 1.85M | 16.5M | 803.5K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -128.3M | -155.5M | -116.4M | -94.6M | -75.4M | -37.3M | -2.75M | -28.3M | -16.9M |
| Capital spending | -374.0K | -3.85M | -921.0K | -1.76M | -1.95M | -1.53M | -964.0K | -2.32M | -1.41M |
| Free cash flow | -128.7M | -159.4M | -117.3M | -96.4M | -77.4M | -38.8M | -3.71M | -30.7M | -18.3M |
| Cash from investing | 134.3M | 140.3M | -127.0M | -150.2M | 73.7M | -210.9M | -17.9M | -2.32M | -1.41M |
| Cash from financing | -31.7M | 23.1M | 274.4M | 226.9M | 2.53M | 213.2M | 45.5M | 87.3M | 20.0M |
| Share buybacks | 215.6M | 2.53M | 213.2M | 48.1M | 87.3M | -12.0K | |||
| Change in cash | -25.7M | 7.95M | 31.0M | -18.0M | 783.0K | -34.9M | 24.9M | 56.7M | 1.68M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 3 · Initial statement of ownership | Jul 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 3 · Initial statement of ownership | Jul 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 13, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 22, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 22, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 17, 2026 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Apr 7, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 2, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 2, 2026 | Other filings | SEC |
| S-3 · Registration statement | Mar 30, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 30, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 11, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 11, 2026 | Results | SEC |
| 10-K · Annual report | Mar 11, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 3, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 9, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 22, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 8, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Dec 22, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 16, 2025 | Management or board change | SEC |
| 8-K · Current report | Dec 8, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 8-K · Current report | Oct 24, 2025 | Management or board change | SEC |
| 8-K · Current report | Oct 20, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 4, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 6, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 9, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 8-K · Current report | May 1, 2025 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2025 | Meeting notice | SEC |
| PRER14A | Apr 11, 2025 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Apr 10, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 13, 2025 | Material contract | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Mar 13, 2025 | Other filings | SEC |
| SCHEDULE 13D · Big-stake notice | Mar 10, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 7, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Mar 3, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 3, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 3, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 13, 2025 | Current report | SEC |
| 8-K · Current report | Feb 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 22, 2025 | Other filings | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Oct 4, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Sep 27, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2024 | Results | SEC |
| 8-K · Current report | Jul 15, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 17, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 14, 2024 | Management or board change | SEC |
| 8-K · Current report | May 14, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2024 | Results | SEC |
| 4 · Change in ownership | May 6, 2024 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 22, 2024 | Meeting notice | SEC |
| 8-K · Current report | Mar 12, 2024 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2024 | Offer document | SEC |
| 10-K · Annual report | Feb 27, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 5, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Jan 25, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 8-K · Current report | Oct 3, 2023 | Material contract | SEC |
| 8-K · Current report | Sep 26, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 9, 2023 | Results | SEC |
| 4 · Change in ownership | Aug 7, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 3, 2023 | Other filings | SEC |
| 4 · Change in ownership | Jul 21, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 20, 2023 | Other filings | SEC |
| 4 · Change in ownership | Jul 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2023 | Insider trade | SEC |
This page holds 200 of 440 filings. Open Filings
Cap table
Built by 6ix from Pliant Therapeutics, Inc.’s releases · as of Nov 9, 2026
- Common shares
- 61,990,635
- Fully diluted
- 61,990,635
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 61,990,635 | Nov 9, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 9, 2026 | 61,990,635 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Suzanne L. Bruhn Other companies: Definium Therapeutics, Inc. (Director · Since at least Aug 11, 2022); Vigil Neuroscience Inc (Director · Since at least Jul 27, 2022); Travere Therapeutics, Inc. (Director · Since at least Apr 8, 2020); Avalo Therapeutics, Inc. (Director · Apr 24, 2020 – Nov 10, 2021 · Past); Novelion Therapeutics Inc (Director · Oct 1, 2017 – Aug 9, 2018 · Past); Spyre Therapeutics, Inc. (Director · Feb 15, 2017 – Jun 8, 2020 · Past); Raptor Pharmaceutical Corp (Director · Sep 25, 2012 – Oct 24, 2016 · Past) | Director · Since at least Jun 2, 2020 |
| Charles Homcy Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); BridgeBio Pharma, Inc. (Director · Since at least Jun 27, 2019); Population Health Investment Co Inc (Director · Nov 17, 2020 – Jan 26, 2021 · Past); Portola Pharmaceuticals Inc (Director · Jun 8, 2018 – Jan 2, 2019 · Past); Global Blood Therapeutics Inc (Director · Oct 3, 2017 – Jun 20, 2018 · Past) | Director · Jun 2, 2020 – Jun 29, 2021 · Past |
| David Pyott Other companies: Tarsus Pharmaceuticals, Inc. (Director · Since at least Feb 18, 2026); Alnylam Pharmaceuticals, Inc. (Chair · Since at least Dec 18, 2015); BioMarin Pharmaceutical Inc. (Director · Jan 4, 2016 – May 21, 2024 · Past); Edwards Lifesciences Corporation (Director · May 12, 2006 – May 9, 2014 · Past); Avery Dennison Corporation (Director · Mar 31, 2006 – Apr 23, 2020 · Past) | Director · Since at least Jan 12, 2021 |
| Neil Exter Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); Decibel Therapeutics Inc (Director · Feb 11, 2021 – Jun 17, 2022 · Past); Revolution Medicines, Inc. (Director · Feb 12, 2020 – Jun 16, 2022 · Past); Rhythm Pharmaceuticals, Inc. (Director · Oct 4, 2017 – Jun 6, 2018 · Past); CytomX Therapeutics, Inc. (Director · Oct 7, 2015 – Jun 20, 2017 · Past) | Director · Jun 2, 2020 – Jun 16, 2022 · Past |
| Robert Iannone Other companies: Autolus Therapeutics plc (Chair of the Research & Development Committee · Since at least Mar 18, 2026); Jazz Pharmaceuticals plc (EVP, Global Head of R&D & CMO · Since at least May 29, 2019); Iteos Therapeutics Inc (Director · Apr 29, 2021 – Jun 11, 2024 · Past); Jounce Therapeutics Inc (Director · Jan 21, 2020 – May 3, 2023 · Past); Immunomedics Inc (CHIEF MEDICAL OFFICER · Apr 12, 2018 – Mar 14, 2019 · Past) | Director · Since at least Jul 9, 2026 |
| Gayle Crowell Other companies: Hercules Capital, Inc. (Director · Since at least Feb 4, 2019); Envestnet Inc (Director · Mar 29, 2016 – Nov 25, 2024 · Past); Yodlee Inc (Director · Oct 2, 2014 – Nov 19, 2015 · Past); Scientific Learning Corporation (Director · Nov 2, 2010 – May 20, 2012 · Past) | Board Member · Since at least Jun 2, 2020 |
| Katharine Knobil Other companies: Korro Bio, Inc. (Director · Since at least Aug 26, 2024); Marker Therapeutics, Inc. (Chief Medical Officer, Altesa BioSciences, Inc. · Since at least Dec 8, 2021); Arena Pharmaceuticals Inc (Director · Jun 12, 2020 – Mar 11, 2022 · Past); Kaleido Biosciences, Inc. (Chief Medical Officer · Feb 27, 2019 – Oct 15, 2020 · Past) | Director · Since at least Sep 14, 2022 |
| Steve Krognes Other companies: argenx SE (Non-executive director, Chairperson of the Audit and Compliance Committee, Member of the Remuneration & Nomination Committee · Since at least Nov 6, 2026); Denali Therapeutics Inc. (Director · Since at least Jul 19, 2022); Guardant Health, Inc. (Director · Since at least Jun 30, 2022); Gritstone bio, Inc. (Director · Jun 17, 2022 – Jun 16, 2023 · Past) | Director · Since at least Jun 13, 2024 |
| Darren Cline Other companies: Xenon Pharmaceuticals Inc. (Chief Commercial Officer · Since at least Jun 23, 2025); Pyxis Oncology, Inc. (Director · Since at least Mar 26, 2024) | Board Member · Since at least Jun 13, 2024 |
| Flavia Borellini Other companies: Revolution Medicines, Inc. (Director · Since at least Jun 22, 2021); Viracta Therapeutics Inc (Director · Aug 14, 2021 – Jun 20, 2024 · Past) | Director · Since at least Jul 9, 2026 |
All 26 people
| Person | Seat |
|---|---|
| Smital Shah Other companies: Lyell Immunopharma, Inc. (Chief Financial and Business Officer · Since at least Mar 9, 2026); LENZ Therapeutics, Inc. (Director · Apr 15, 2021 – Jul 19, 2023 · Past) | Director · Jun 2, 2020 – Jun 13, 2024 · Past |
| Bernard Coulie Other companies: Septerna, Inc. (Director · Since at least Oct 24, 2024) | Director · Since at least Jun 2, 2020 |
| Hans Hull Other companies: Adverum Biotechnologies Inc (Chief Executive Officer · Jul 30, 2014 – Aug 21, 2015 · Past) | Chief Business Officer · Jun 2, 2020 – Jan 23, 2025 · Past |
| Hoyoung Huh Other companies: Akari Therapeutics PLC (Chairman · Since at least Nov 14, 2024) | Director · Since at least Jun 16, 2022 |
| Thomas McCourt Other companies: Ironwood Pharmaceuticals, Inc. (Chief Executive Officer, Director · Since at least May 23, 2022) | Director · Since at least Mar 6, 2023 |
| Barbara Howes | Chief Human Resource Officer · Jun 2, 2020 – Jan 23, 2021 · Past |
| Craig Blanchette | Senior Vice President, Research · Since at least Oct 20, 2026 |
| David Raben | Chief Medical Officer · Since at least Sep 30, 2026 |
| Eric Lefebvre | Chief Medical Officer · Jun 2, 2020 – Jan 23, 2025 · Past |
| John Curnutte | Director · Since at least Jun 5, 2025 |
| Katerina Leftheris | Director · Jan 9, 2026 – Nov 5, 2026 · Past |
| Keith Lamont Cummings | Chief Financial Officer · Since at least Jan 17, 2024 |
| Lily Cheung | Chief Human Resource Officer · Since at least Jan 23, 2024 |
| Mike Ouimette | General Counsel & Corp. Sec'y · Oct 1, 2020 – Jan 23, 2025 · Past |
| Minnie Kuo | Chief Operating Officer · Since at least Dec 10, 2025 |
| Steve Krognes | Member · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Pliant Therapeutics, Inc.